2010 Annual Scientific Meeting and Exposition 2010 Annual ...

More documents

Recommendations

Info

MAY 1SessionsSaturday Afternoon4:00 PM – 5:00 PM • Rendezvous TrianonYoung Investigator-in-Training AbstractCompetitionModerator: Suzanne Oparil, MD, Birmingham, ALJudges: John M. Flack, MD, MPH, Detroit, MI, Alan H.Gradman, MD, Pittsburgh, PA, Daniel T. Lackland,DrPH, Charleston, SC, Sandra J. Taler, MD, Rochester,MN and Myron H. Weinberger, MD, Indianapolis, IN4:00 PM OR-35: Efficacy and Safety of Dual Calcium Channel(CCB) TherapyCarlos L. Alviar, Santhosh Devarapally, Jorge Romero,Hyuensok Kang, Girish N. Nadkarni, Fahad Javed,Alexandre M. Benjo, Franz Messerli. St. Luke’s-Roosevelt Hospital Center, Columbia UniversityCollege of Physicians and Surgeons, New York, NY,US.4:12 PM OR-37: Refractory Hypertension: Definition,Prevalence, and Patient CharacteristicsMaria Czarina Acelajado, David A. Calhoun.University of Alabama at Birmingham, Birmingham,AL, US.4:24 PM OR-38: Abnormal Regulation of the Renin-Angiotensin-Aldosterone System in ObeseHypertensive MenCamilla Asferg, Ulrik B. Andersen, Jørgen Jeppesen.Copenhagen University Hospital Glostrup, Glostrup,DK.4:36 PM OR-39: Mapping a Genetic Determinant of BloodPressure to
Sunday Morning MAY 2Satellite Symposium6:00 AM – 7:30 AM • Trianon BallroomThe Journey to Optimal Treatment Strategies forthe OA Patient with HypertensionChairperson: Michael A. Weber, MD, Brooklyn, NYProgram Agenda:6:00 AM Welcome and IntroductionsMichael A. Weber, MD6:10 AM NSAIDs, Blood Pressure and Cardiovascular Risk:Understanding the Risks for Osteoarthritis PatientsAndrew Whelton, MD, Baltimore, MD6:30 AM Nitric Oxide: The Journey from Basic Biology toTherapeutic PotentialLeopoldo Raij, MD, Miami, FL6:55 AM CINODs: A New Option in the Management ofOsteoarthritis Patients with HypertensionMichael A. Weber, MD7:20 AM Panel Discussion/Questions and AnswersAll FacultyLearning Objectives:• Review the current available options for thetreatment of osteoarthritis (OA) and evaluatetheir potential benefits and risks• Discuss the relationship of backgroundantihypertensive therapy in NSAID-inducedblood pressure destabilization• Summarize the outcomes associated withendothelial dysfunction and decreasedbioavailability of nitric oxide• Evaluate the data and potential utility ofCyclooxygenase-Inhibiting Nitric Oxide Donating(CINOD) drugsBreakfast will be served at 5:45 AM in theTrianon Ballroom.Supported by an educational grant from NicOx, Inc.61
Page 1 and 2:
American Society of Hypertension201
Page 3 and 4:
Valturna offers bothsuperior BP eff
Page 5 and 6:
Figure 2: Probability of Achieving
Page 7 and 8:
potential for other drugs acting on
Page 9 and 10:
aliskiren arms were about one-third
Page 11 and 12: As with other drugs that block angi
Page 13: American Society of Hypertension201
Page 18: Program Color KeyThe pages of this
Page 21 and 22: General InformationThis program boo
Page 23 and 24: General Information continuedHilton
Page 25 and 26: General Information continuedASH Sc
Page 27 and 28: General Information continuedASH Hy
Page 29 and 30: 2010 ASH Corporate MembersBoehringe
Page 31 and 32: ASH Leadership2009-2010 Board of Di
Page 33 and 34: Special LectureMonday, May 3, 2010,
Page 35 and 36: Special LectureMonday, May 3, 2010,
Page 37 and 38: 2010 Abstract Reviewers continuedEr
Page 39 and 40: Visit TEKTURNA at Booth 1100.and/or
Page 41 and 42: 5.5 HyperkalemiaIncreases in serum
Page 43 and 44: with Pgp substrates or weak to mode
Page 45 and 46: ASH Program at a GlanceSaturday, Ma
Page 47 and 48: ASH Program at a GlanceMonday, May
Page 49 and 50: Poster Category PresentationPosters
Page 51 and 52: 2010 ASH Faculty continuedJeffrey R
Page 53 and 54: 2010 ASH Faculty continuedAndrew Wh
Page 55 and 56: 2010American Societyof Hypertension
Page 57 and 58: Saturday Afternoon MAY 1PostersPost
Page 59 and 60: Saturday Afternoon MAY 1Sessions3:3
Page 61: Saturday Afternoon MAY 1Sessions3:3
Page 65 and 66: Sunday Morning MAY 2Sessions contin
Page 67 and 68: Sunday Morning MAY 2Sessions8:00 AM
Page 69 and 70: Sunday Morning MAY 2Sessions10:00 A
Page 71 and 72: Sunday Morning MAY 2Sessions10:00 A
Page 73 and 74: Sunday Afternoon MAY 2Sessions3:30
Page 75 and 76: Sunday Afternoon MAY 2Sessions3:30
Page 77 and 78: Sunday Afternoon MAY 2Special Sessi
Page 79 and 80: Sunday Evening MAY 2Sessions6:00 PM
Page 81 and 82: Sunday Evening MAY 2Sessions6:00 PM
Page 83 and 84: Monday Morning MAY 3Satellite Sympo
Page 85 and 86: Monday Morning MAY 3Sessions8:00 AM
Page 87 and 88: Monday Morning Afternoon MAY 21 3Po
Page 89 and 90: Monday Morning MAY 3Sessions10:00 A
Page 95 and 96: Monday Evening May 3Satellite Sympo
Page 97 and 98: Tuesday Morning May 48:45 AM LB-OR-
Page 99 and 100: Tuesday Morning May 4Sessions8:00 A
Page 101 and 102: Tuesday Morning MAY 4ASH Membership
Page 103 and 104: Tuesday Morning MAY 4Sessions10:55
Page 105 and 106: 2010American Societyof Hypertension
Page 107 and 108: Saturday Afternoon MAY 1Posters3:00
Page 109 and 110: Saturday Afternoon MAY 1PostersPO-2
Page 111 and 112: Saturday Afternoon MAY 1PostersPO-3
Page 113 and 114:
Saturday Afternoon MAY 1PostersPO-4
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Sunday Morning MAY 2PostersPosters
Page 127 and 128:
Sunday Morning MAY 2Posters9:00 AM
Page 129 and 130:
Sunday Morning MAY 2PostersPO-123:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Monday Morning Afternoon MAY 21 3Po
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Monday Morning Afternoon May 213Pos
Page 163 and 164:
Faculty Disclosure ListingGail Adle
Page 165 and 166:
Faculty Disclosure Listing continue
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
you to attend thethe Innovations Th
Page 175 and 176:
5.5 HyperkalemiaIncreases in serum
Page 177 and 178:
with Pgp substrates or weak to mode
Page 179 and 180:
Valturna (aliskiren and valsartan,
Page 181 and 182:
4 CONTRAINDICATIONSNone.5 WARNINGS
Page 183 and 184:
een reported. In a 4-day trial of v
Page 185 and 186:
7 DRUG INTERACTIONSNo drug interact
Page 187 and 188:
8.5 Geriatric UseIn 8.5the Geriatri
Page 189 and 190:
2010 ASH ExhibitorsASH Hypertension
Page 191 and 192:
ASH Hypertension Resource CenterHil
Page 193 and 194:
2010 ASH Exhibitors continuedCVRx I
Page 195 and 196:
2010 ASH Exhibitors continuedIntern
Page 197 and 198:
2010 ASH Exhibitors continuedNature
Page 199 and 200:
2010 ASH Exhibitors continuedRESPeR
Page 201 and 202:
Author IndexAAbaunza, Ricardo, 122A
Page 203 and 204:
Author IndexCastellano, Maurizio, 1
Page 205 and 206:
Author IndexGuarneri, Marco, 146Guo
Page 207 and 208:
Author IndexLekakis, John, 118, 122
Page 209 and 210:
Author IndexPittaras, Andreas, 149P
Page 211 and 212:
Author IndexTello, Susana, 109, 135
Page 213 and 214:
Hilton New York Floor PlansSecond F
Page 215 and 216:
Hilton New York Floor PlansFourth F
Page 218:
Are You 1in 3?Get the facts. Know y
show all

2010 Annual Scientific Meeting and Exposition 2010 Annual ...

Create successful ePaper yourself

Delete template?

Save as template?